Risk of relapse after vedolizumab withdrawal in Inflammatory Bowel Disease for patients in histological remission

被引：0
|
作者：
Blad, W. [1 ]
Whitley, L. [1 ]
Harrow, P. [1 ]
机构：
[1] Univ Coll London Hosp, Dept Gastroenterol, London, England
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P808
引用
收藏
页码：942 / 942
页数：1
相关论文
共 50 条
  • [21] Remission state in Inflammatory Bowel Disease patients on anti TNF or vedolizumab: a confocal endomicroscopy study
    Loly, J. P.
    Vieujean, S.
    Reenaers, C.
    Van Kemseke, C.
    Seidel, L.
    Somja, J.
    Louis, E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I283 - I283
  • [22] Anti-TNF withdrawal according to a risk-stratified protocol does not reduce the risk of relapse in patients with Inflammatory Bowel Disease in endoscopic remission: A prospective study
    Mahmoud, R.
    Savelkoul, E.
    Mares, W.
    Goetgebuer, R.
    Witteman, B.
    de Koning, D.
    Minderhoud, I.
    van Tuyl, S.
    van Boeckel, P.
    Mahmmod, N.
    Lutgens, M.
    Horjus, C.
    Romkens, T.
    Akol-Simsek, D.
    Jansen, J.
    Hoentjen, F.
    Jharap, B.
    Oldenburg, B.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I113 - I114
  • [23] Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients
    Kennedy, N. A.
    Kalla, R.
    Warner, B.
    Gambles, C. J.
    Musy, R.
    Reynolds, S.
    Dattani, R.
    Nayee, H.
    Felwick, R.
    Harris, R.
    Marriott, S.
    Senanayake, S. M.
    Lamb, C. A.
    Al-Hilou, H.
    Gaya, D. R.
    Irving, P. M.
    Mansfield, J.
    Parkes, M.
    Ahmad, T.
    Cummings, J. R. F.
    Arnott, I. D.
    Satsangi, J.
    Lobo, A. J.
    Smith, M.
    Lindsay, J. O.
    Lees, C. W.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (11-12) : 1313 - 1323
  • [24] Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease
    Helwig, Ulf
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2017, 55 (01): : 85 - 85
  • [25] Histological remission in inflammatory bowel disease and risk of adverse pregnancy outcomes: A nationwide study
    Marild, Karl
    Soderling, Jonas
    Stephansson, Olof
    Axelrad, Jordan
    Halfvarson, Jonas
    Broms, Gabriella
    Marsal, Jan
    Olen, Ola
    Ludvigsson, Jonas F.
    ECLINICALMEDICINE, 2022, 53
  • [26] The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
    Choi, Myeong Geun
    Ye, Byong Duk
    Yang, Suk-Kyun
    Shim, Tae Sun
    Jo, Kyung-Wook
    Park, Sang Hyoung
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (14)
  • [27] Ustekinumab and vedolizumab influence on cardiovascular risk factors in patients with Inflammatory Bowel Disease
    Amiama Roig, C.
    Suarez Ferrer, C.
    Poza Cordon, J.
    Rueda Garcia, J. L.
    Sanchez Azofra, M.
    Martin Arranz, E.
    Gonzalez Diaz, I.
    Amor Costa, C.
    Garcia Ramirez, L.
    Martin Arranz, M. D.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S462 - S463
  • [28] Life events and inflammatory bowel disease relapse:: A prospective study of patients enrolled in remission
    Vidal, A
    Gómez-Gil, E
    Sans, M
    Portella, MJ
    Salamero, M
    Piqué, JM
    Panés, J
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (04): : 775 - 781
  • [29] Life events and inflammatory bowel disease relapse: A prospective study of patients enrolled in remission
    Vidal, Angela
    Gil, Esther Gomez
    Sans, Miquel
    Maria, Portella J.
    Salamero, M.
    Josep, Pique M.
    Panes, Julian
    GASTROENTEROLOGY, 2006, 130 (04) : A644 - A644
  • [30] SAFETY OF VEDOLIZUMAB USE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Shivashankar, Raina
    Ladd, Antonio H. Mendoza
    Grace, Rory
    Aberra, Faten
    Lichtenstein, Gary R.
    GASTROENTEROLOGY, 2017, 152 (05) : S585 - S585
12345